Drugs / Conditionally replicative adenovirus 3/5-delta
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01531244 | Dec 2014 → Feb 2016 | melanoma | Washington University School of Medicine | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Conditionally replicative adenovirus 3/5-delta | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01531244 ↗ |
| Route | Other | “Patients then receive CRAd 3/5-delta via ILI” NCT01531244 ↗ |